Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:R07AX02
|
| gptkbp:brand |
gptkb:Orkambi
|
| gptkbp:CASNumber |
936727-05-8
|
| gptkbp:combines |
gptkb:ivacaftor
|
| gptkbp:developedBy |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
26 hours
|
| gptkbp:hasMolecularFormula |
C24H18F2N2O5
|
| gptkbp:hasSMILES |
CC1=CC(=O)NC(=O)N1C2=CC=C(C=C2)C3=CC=C(C=C3)C4=CC(=C(C=C4)F)F
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lumacaftor
|
| gptkbp:KEGGID |
D10541
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
CFTR corrector
|
| gptkbp:PubChem_CID |
CHEMBL2105758
DB09280 46209116 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue shortness of breath |
| gptkbp:target |
gptkb:CFTR_protein
|
| gptkbp:UNII |
6P7Y4YHF6E
|
| gptkbp:usedFor |
cystic fibrosis
|
| gptkbp:bfsParent |
gptkb:CFTR
|
| gptkbp:bfsLayer |
7
|